LADW
LADW is a tetrapeptide derived from the hydrolysate of tuna skeletal muscle myosin, with dual inhibitory activities against angiotensin-converting enzyme 1 (ACE1) and α-glucosidase. The IC50 value of LADW against ACE1 is 28.02 μM, while its IC50 value against Saccharomyces cerevisiae α-glucosidase is 4.40 mM. LADW binds competitively to the active site of ACE1, stabilizes the enzyme conformation, and blocks substrate binding. LADW binds to α-glucosidase to inhibit carbohydrate hydrolysis and can also alter starch structure. LADW can be used in studies related to hypertension and diabetes.
For research use only. We do not sell to patients.
- Formula: C24H33N5O7
- Molecular Weight:503.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
LADW is a competitive inhibitor of purified ACE1, which binds to the active site of the enzyme or its adjacent region to block substrate binding. It potently inhibits purified ACE1 with an IC50 of 28 μM, exhibiting a concentration-dependent inhibitory effect[1].
LADW (150-300 μM; 24 h) promotes NO release and inhibits ET-1 secretion in EA.hy926 vascular endothelial cells in a concentration-dependent manner[1].
LADW forms strong interactions with eNOS, ECE-1 and Furin via hydrogen bonds and van der Waals forces and binds to the key active residues of these proteins according to molecular docking results[1].
LADW (15 min pre-incubation followed by 15 min reaction) potently inhibits α-glucosidase derived from Saccharomyces cerevisiae, with an IC50 value of 4.40 mM, and its inhibitory activity is stronger than that of EEAEGT[2].
LADW inhibits the hydrolysis of soluble starch during simulated gastrointestinal digestion by altering starch structure, reducing the production of reducing sugars by 39.56%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:EA.hy926 vascular endothelial cells
-
Concentration:150 μM, 300 μM
-
Incubation Time:24 h
-
Result:Increased NO release by 45.88% (150 μM) and 78.94% (300 μM) compared to controls.
Reduced ET-1 secretion by 22.34% (150 μM) and 60.79% (300 μM) compared to controls.
Chemical Information
-
Molecular Weight 503.55
-
Formula C24H33N5O7
-
Sequence
Leu-Ala-Asp-Trp
-
Sequence Shortening
LADW
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)